Latest Breast cancer treatment Stories
More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures – including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis.
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity.
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes.
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab.
- A trick or prank.